Samsara BioCapital

Samsara Biocapital is seeking to raise $500 million for its new fund, according to an SEC filing.

Chinook Therapeutics, a Vancouver-based developer of precision medicines for kidney disease, has raised about $86 million (US$65 million) in a Series A financing. U.S. life sciences venture capital firm Versant Ventures led the round, with participation from Apple Tree Partners and Samsara BioCapital. Chinook was incubated through Versant's Inception Sciences and seeded by Versant and Apple Tree. Chinook's technology leverages single-cell RNA sequencing, human-derived organoids and new translational models to develop therapeutics with novel mechanisms of action against kidney disease pathways. Led by President and CEO Eric Dobmeier, the company will use the funds raised to advance several programs into clinical trials by 2021.

Velicept Therapeutics, a clinical stage pharmaceutical company focused on treating urological and gastrointestinal disorders, has raised $15 million in funding. Samsara BioCapital led the round. In conjunction with the funding, Cory Freedland, a principal at Samsara BioCapital, has joined Velicept's board of directors.

South San Francisco-based Sutro Biopharma Inc, a drug developer, has secured $85.4 million in Series E financing. Samsara BioCapital and Surveyor Capital led the round with participation from other investors that included Alta Partners, Amgen Ventures, Celgene Corporation, Lilly Ventures, Skyline Ventures and SV Health Investors. In addition to the funding, Dr. Mike Dybbs, a partner at Samsara BioCapital, will join the Sutro board of directors.

Samsara BioCapital has raised $310 million for a venture-capital fund, according to a filing with the SEC.

Samsara BioCapital has raised $260.6 million toward a $300 million venture-capital fund, according to a filing with the SEC.

Samsara BioCapital has set out to raise a $300 million venture fund, according to a filing with the SEC.

Lightspeed Venture Partners and Ascenta Capital led the round.

ImmunOs Therapeutics AG, a biopharmaceutical company, has raised $74 million in Series B financing.

San Diego and Vancouver-based biotechnology company Tentarix Biotherapeutics secured $50 million in Series A financing.

Neurogastrx, a developer of treatments for gastrointestinal disorders, has secured $60 million in Series B funding.

Prime Medicine, a biotech company, has raised $200 million in Series B funding.

Graphite Bio, a gene editing company focused on treating or curing serious diseases, has raised $238 million for its IPO after pricing its 14 million shares at $17 per share.

Janux Therapeutics, a biopharmaceutical company, has raised $193.8 million for its IPO after pricing its 11.4 million shares at $17 per share.

Rain Therapeutics, a developer of precision oncology therapeutics, has raised about $125 million for its IPO after pricing its over 7.3 million shares at $17 per share.